178 related articles for article (PubMed ID: 24215035)
1. How I treat nodular lymphocyte predominant Hodgkin lymphoma.
Advani RH; Hoppe RT
Blood; 2013 Dec; 122(26):4182-8. PubMed ID: 24215035
[TBL] [Abstract][Full Text] [Related]
2. [Nodular lymphocyte-predominant Hodgkin lymphoma in children: clinical course, biology, and management].
Gorde-Grosjean S; Guimard G; Lambilliotte A; Coulomb-Lhermine A; Montravers F; Landman-Parker J
Bull Cancer; 2014 Sep; 101(9):881-90. PubMed ID: 25296072
[TBL] [Abstract][Full Text] [Related]
3. Lymphocyte-predominant Hodgkin lymphoma: what is the optimal treatment?
Fanale M
Hematology Am Soc Hematol Educ Program; 2013; 2013():406-13. PubMed ID: 24319212
[TBL] [Abstract][Full Text] [Related]
4. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma.
Advani RH; Horning SJ; Hoppe RT; Daadi S; Allen J; Natkunam Y; Bartlett NL
J Clin Oncol; 2014 Mar; 32(9):912-8. PubMed ID: 24516013
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).
Schulz H; Rehwald U; Morschhauser F; Elter T; Driessen C; Rüdiger T; Borchmann P; Schnell R; Diehl V; Engert A; Reiser M
Blood; 2008 Jan; 111(1):109-11. PubMed ID: 17938252
[TBL] [Abstract][Full Text] [Related]
6. Nodular lymphocyte-predominant Hodgkin lymphoma.
Fuchs M; Eichenauer DA; Nogová L; Diehl V; Engert A;
Curr Hematol Malig Rep; 2008 Jul; 3(3):126-31. PubMed ID: 20425457
[TBL] [Abstract][Full Text] [Related]
7. Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management.
Eichenauer DA; Engert A
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):324-328. PubMed ID: 29222274
[TBL] [Abstract][Full Text] [Related]
8. Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma.
Spinner MA; Varma G; Advani RH
Br J Haematol; 2019 Jan; 184(1):17-29. PubMed ID: 30485408
[TBL] [Abstract][Full Text] [Related]
9. The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma.
Maeda LS; Advani RH
Curr Opin Oncol; 2009 Sep; 21(5):397-400. PubMed ID: 19606035
[TBL] [Abstract][Full Text] [Related]
10. Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era.
King MT; Donaldson SS; Link MP; Natkunam Y; Advani RH; Hoppe RT
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):67-75. PubMed ID: 25863755
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma versus those with classical Hodgkin lymphoma: a population-based analysis.
Gerber NK; Atoria CL; Elkin EB; Yahalom J
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):76-83. PubMed ID: 25863756
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group.
Eichenauer DA; Fuchs M; Pluetschow A; Klimm B; Halbsguth T; Böll B; von Tresckow B; Nogová L; Borchmann P; Engert A
Blood; 2011 Oct; 118(16):4363-5. PubMed ID: 21828141
[TBL] [Abstract][Full Text] [Related]
13. Modern management of lymphocyte-predominant Hodgkin lymphoma.
Xing KH; Savage KJ
Br J Haematol; 2013 May; 161(3):316-29. PubMed ID: 23398605
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of rituximab treatment in patients with progressive transformation of germinal centers after Hodgkin lymphoma in complete remission post-induction chemotherapy and radiotherapy.
Picardi M; Zeppa P; Ciancia G; Pettinato G; Grimaldi F; Fabbricini R; Mainolfi C; Pane F
Leuk Lymphoma; 2011 Nov; 52(11):2082-9. PubMed ID: 21663508
[TBL] [Abstract][Full Text] [Related]
15. Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis.
Xing KH; Connors JM; Lai A; Al-Mansour M; Sehn LH; Villa D; Klasa R; Shenkier T; Gascoyne RD; Skinnider B; Savage KJ
Blood; 2014 Jun; 123(23):3567-73. PubMed ID: 24713929
[TBL] [Abstract][Full Text] [Related]
16. How I treat nodular lymphocyte-predominant Hodgkin lymphoma.
Eichenauer DA; Engert A
Blood; 2020 Dec; 136(26):2987-2993. PubMed ID: 32877522
[TBL] [Abstract][Full Text] [Related]
17. The unique entity of nodular lymphocyte-predominant Hodgkin lymphoma: current approaches to diagnosis and management.
Hawkes EA; Wotherspoon A; Cunningham D
Leuk Lymphoma; 2012 Mar; 53(3):354-61. PubMed ID: 21812538
[TBL] [Abstract][Full Text] [Related]
18. Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year follow-up in the West of Scotland Cancer Network.
Farrell K; McKay P; Leach M
Leuk Lymphoma; 2011 Oct; 52(10):1920-8. PubMed ID: 21663507
[TBL] [Abstract][Full Text] [Related]
19. Nodular lymphocyte predominant Hodgkin lymphoma.
Lee AI; LaCasce AS
Oncologist; 2009 Jul; 14(7):739-51. PubMed ID: 19605845
[TBL] [Abstract][Full Text] [Related]
20. Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma.
Nogová L; Rudiger T; Engert A
Hematology Am Soc Hematol Educ Program; 2006; ():266-72. PubMed ID: 17124071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
